Pancreatic progenitor cells derived from human embryonic stem or induced pluripotent stem cells hold tremendous potential for modeling pancreatic development and disease, as well as for regenerative therapies addressing degenerative conditions like diabetes. The ability to direct differentiation of pancreatic progenitor cells to specific endocrine cell types has led researchers to propose human pluripotent stem cells as an unlimited source of insulin-producing beta cells for studying and treating diabetes. In this webinar, Dr. Ray Dunn and Dr. Jamie Trott (A*STAR Institute for Medical Biology, Singapore) present their data on generating pancreatic progenitors and beta cells from diabetic-patient-derived induced pluripotent stem cells.